Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital

Bone Marrow Transplantation
I IlariR Cozza

Abstract

We report the toxicity of high-dose chemotherapy (HDC) based on etoposide, thiotepa and CY (ETC) in children with poor-prognosis Ewing's sarcoma family tumors (ESFTs). A total of 26 patients with high-risk ESFT (metastasis or axis localization or tumor volume >200 ml or necrosis <95%) were reviewed. The conditioning was based on etoposide (600 mg/m(2)), thiotepa (750 mg/m(2)) and CY (120 mg/kg) followed by autologous BM or PBSC rescue. The conditioning regimen was well tolerated, without any toxic deaths. The median time from transplant to a neutrophil count of >0.5 x 10(9)/l was 10 days (range 6-27) and 22.5 days (range 9-114) for a plt count of >50 x 10(9)/l. Oral mucositis was recorded in 20 patients, grade 1/2 in 19 and grade 3 in the last patient. Diarrhea grade 1/2 was recorded in four patients and grade 1/2 liver toxicity in four patients. Sepsis was documented in four cases and skin toxicity in three. Lung and tubular toxicity, respectively, were reported in one patient each. We conclude that the ETC regimen presented a limited and manageable toxicity. Further studies would confirm the role of ETC in high-risk ESFT.

References

Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S I BearmanE D Thomas
Jul 1, 1988·International Journal of Radiation Oncology, Biology, Physics·R B MarcusR R Million
Jan 1, 1987·Journal of Cancer Research and Clinical Oncology·V GöbelU Göbel
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BurdachE Koscielniak
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M E HorowitzR G Steis
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B RaneyH M Maurer
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P PicciF Bertoni
Jun 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A W CraftD Pearson
Dec 24, 1997·Bone Marrow Transplantation·A AtraC R Pinkerton
May 29, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M PaulussenH Jürgens
May 29, 1998·Bone Marrow Transplantation·L MaderoS Salas
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G BacciP Picci
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J CotterillA W Craft
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M PaulussenH Jürgens
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A MeyersR G Gorlick
Mar 26, 2003·Medical and Pediatric Oncology·Carlos Rodriguez-GalindoAlberto S Pappo
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S BurdachH Juergens
May 25, 2006·The Oncologist·Mark BernsteinHerbert Juergens
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Odile OberlinUNKNOWN Société Française des Cancers de l'Enfant
Sep 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael PaulussenUNKNOWN European Intergroup Cooperative Ewing's Sarcoma Study-92

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.